Therefore, being able to inhibit ABL and FLT3, the most promising hematological use for Aurora kinase inhibitors seem to be in Philadelphia chromosome-positive leukemias and FLT3-mutated acute myeloid leukemia, respectively. Here, FLT3 is linked to acute myeloid leukemia.